Gattefossé is investing 30 million euros in its industrial operations and announces the construction of a new manufacturing plant in Lufkin, Texas. This asset will produce lipid-based specialty ingredients for the personal care and pharmaceutical industries.
Construction will begin in 2021 and the plant should deliver its first customers in 2024.
“North America is a leading region for the global pharmaceutical and personal care industries in terms of innovation, production and consumption, and has therefore a major impact on worldwide trends. The opening of a manufacturing unit represents an essential milestone in our strategy to enhance our local presence and commitment to this important and influential market. The label ‘Made in USA’ will satisfy a strong demand expressed by our customers and the geographical location of this new site will facilitate logistics and supply chain. Production in Texas is first intended to serve the North American market but will gradually be extended to other regions," Eric Brun, President and CEO of Gattefossé USA and Canada the Gattefossé Group operates 2 production sites, in Europe (France) and Asia (Singapore).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
The opening of a third manufacturing plant in the United States will improve the Group's ability to better serve the American market and represents an extra step in the deployment of its industrial operations.